Biomatrix Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biomatrix Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 15 Products, $25.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biomatrix Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 15 Products, $25.7M Trade | TransData Nexus

Biomatrix Healthcare Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $25.7M Total Trade · DGFT Verified

Biomatrix Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $25.7M across 15 products in 6 therapeutic categories. Based on 676 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amoxicillin ($5.0M), Artemether ($4.0M), Metronidazole ($3.1M).

Biomatrix Healthcare Private Limited — Export Portfolio & Destination Treemap

Biomatrix Healthcare Private Limited pharmaceutical export portfolio — 15 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Biomatrix Healthcare Private Limited? — Company Overview & Market Position

Biomatrix Healthcare Private Limited, established on November 22, 2007, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24232GJ2007PTC052214. As of March 2026, Biomatrix Healthcare has an authorized capital of ₹4.5 crore and a paid-up capital of ₹4.01 crore. The company's registered office is located at Fifth Floor-502/B, Time Square Grand, Near Sindhu Bhavan, Ahmedabad, Gujarat 380059, India.

Biomatrix Healthcare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a diverse product portfolio encompassing 15 products across six therapeutic categories. In the fiscal year 2022-2026, Biomatrix Healthcare reported a total export value of $25.7 million USD, with 676 shipments. The top five exported products are Amoxicillin ($5.0 million), Artemether ($4.0 million), Metronidazole ($3.1 million), Clindamycin ($3.1 million), and Artesunate ($2.8 million). The primary therapeutic categories include Antibiotics (37.5%), Antimalarial & Antiparasitic (26.5%), and Respiratory & OTC (16.6%). The company's portfolio concentration is notable, with the top five products accounting for 70.1% of total exports.

What Does Biomatrix Healthcare Private Limited Export? — Product Portfolio Analysis

Product Portfolio — Top 15 by Export Value

Biomatrix Healthcare Private Limited exports 15 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$5.0M	100	0.8%	10
2	Artemether	Antimalarial & Antiparasitic	$4.0M	81	0.5%	14
3	Metronidazole	Advanced Antibiotics	$3.1M	64	1.6%	8
4	Clindamycin	Antibiotics	$3.1M	62	3.4%	6
5	Artesunate	Antimalarial & Antiparasitic	$2.8M	98	1.6%	7
6	Phenylephrine	Respiratory & OTC	$1.8M	38	2.1%	8
7	Caffeine	Respiratory & OTC	$1.4M	75	1.3%	15
8	Erythromycin	Antibiotics	$1.3M	46	1.6%	9
9	Ambroxol	Respiratory & OTC	$1.1M	24	7.3%	3
10	Enalapril	Cardiovascular	$850.0K	17	0.4%	12
11	Flucloxacillin	Advanced Antibiotics	$278.0K	22	0.7%	15
12	Ornidazole	Advanced Antibiotics	$257.4K	22	1.5%	5
13	Cephalexin	Antibiotics	$250.0K	5	0.1%	9
14	Ibuprofen Paracetamol	Combination Drugs	$244.3K	12	12.7%	2
15	Captopril	Cardiovascular	$243.8K	10	2.0%	4

Biomatrix Healthcare Private Limited exports 15 pharmaceutical products across 6 therapeutic categories with a total export value of $25.7M. The top category is Antibiotics (37.5% of portfolio), followed by Antimalarial & Antiparasitic (26.5%), indicating a concentrated portfolio with the top 5 products accounting for 70.1% of total export value.

Biomatrix Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Biomatrix Healthcare operates a manufacturing facility located at Survey No. 624, Sarkhej-Bavla Highway, Village Rajoda, Taluka Bavla, District Ahmedabad, Gujarat 382220, India. The facility is certified by WHO-GMP, EU-GMP, and Health Canada, ensuring compliance with international quality standards. Additionally, the company adheres to US-FDA, UK-MHRA, and ANVISA regulatory requirements, reflecting its commitment to maintaining high manufacturing standards.

3Key Leadership

The leadership team at Biomatrix Healthcare includes:

Sureshbhai Raghavjibhai Javiya: Director
Labhuben Sureshbhai Javiya: Director
Vijay Sureshbhai Javiya: Director
Dinesh Pyarali Hemnani: Director

These individuals have been instrumental in guiding the company's strategic direction and operational success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Biomatrix Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biomatrix Healthcare has made significant strides in obtaining regulatory approvals for its products in various international markets. In October 2025, the company received site approval from the Food and Drug Administration (FDA) of the Philippines, marking a key milestone in its expansion efforts. Additionally, in the same month, Biomatrix Healthcare secured approval from the Iraqi Ministry of Health, further enhancing its presence in the Middle East. These approvals underscore the company's commitment to meeting global quality standards and expanding its footprint in regulated markets.

2Emerging Markets

Biomatrix Healthcare has strategically focused on expanding its presence in emerging markets, including Africa, Latin America, Southeast Asia, and the Commonwealth of Independent States (CIS). The company's participation in international exhibitions, such as Iphex 2024 and CPHI Frankfurt 2025, has facilitated collaborations and partnerships in these regions. Furthermore, the company's manufacturing facility holds certifications from WHO-GMP, EU-GMP, and Health Canada, which are essential for market access in these regions. These certifications enable Biomatrix Healthcare to meet the regulatory requirements of various countries, thereby enhancing its market penetration in emerging economies.

Geographic Strategy

Biomatrix Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Biomatrix Healthcare's manufacturing facility is registered with the US Food and Drug Administration (FDA), indicating compliance with FDA regulations. The company has also secured approvals from other regulatory bodies, including the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Brazilian Health Regulatory Agency (ANVISA), reflecting its commitment to meeting international quality standards. These approvals facilitate the company's entry into various international markets, including the United States, the United Kingdom, and Brazil.

2WHO & EU GMP

Biomatrix Healthcare's manufacturing facility holds certifications from the World Health Organization Good Manufacturing Practice (WHO-GMP) and the European Union Good Manufacturing Practice (EU-GMP). These certifications validate the company's adherence to stringent quality standards recognized globally. The facility also complies with Health Canada regulations, further demonstrating its commitment to maintaining high manufacturing standards.

3CDSCO & Indian Regulatory

Biomatrix Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Biomatrix Healthcare operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. The company's focus on obtaining international certifications and regulatory approvals positions it favorably in the global market. By diversifying its product portfolio and expanding into emerging markets, Biomatrix Healthcare aims to enhance its market share and competitive standing.

2Key Differentiators

Biomatrix Healthcare's key differentiators include its comprehensive product portfolio, spanning 15 products across six therapeutic categories, and its commitment to quality, as evidenced by certifications from WHO-GMP, EU-GMP, and Health Canada. The company's strategic focus on obtaining regulatory approvals in various international markets further distinguishes it in the competitive landscape.

3Strategic Position

Biomatrix Healthcare's current strategic direction emphasizes expanding its presence in both established and emerging markets through regulatory approvals and partnerships. The company's future outlook includes further diversification of its product portfolio and strengthening its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Biomatrix Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Biomatrix Healthcare has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a commitment to quality. The company's export volume and consistency are supported by its adherence to international certifications and regulatory approvals. Reliability indicators include its compliance with WHO-GMP, EU-GMP, and Health Canada standards, as well as approvals from the FDA, MHRA, and ANVISA.

2Certifications to Verify

Importers should verify the following certifications when considering Biomatrix Healthcare as a supplier:

FDA Registration: Confirm the facility's registration with the US FDA to ensure compliance with US regulations.
WHO-GMP Certification: Verify the facility's certification by the World Health Organization to ensure adherence to international manufacturing standards.
EU-GMP Certification: Check for certification by the European Union to confirm compliance with European manufacturing standards.

Frequently Asked Questions — Biomatrix Healthcare Private Limited

How many pharmaceutical products does Biomatrix Healthcare Private Limited export from India?

Biomatrix Healthcare Private Limited exports 15 pharmaceutical products across 6 therapeutic categories. The top exports are Amoxicillin ($5.0M), Artemether ($4.0M), Metronidazole ($3.1M), Clindamycin ($3.1M), Artesunate ($2.8M). Total export value is $25.7M.

What is Biomatrix Healthcare Private Limited's total pharmaceutical export value?

Biomatrix Healthcare Private Limited's total pharmaceutical export value is $25.7M, based on 676 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Biomatrix Healthcare Private Limited cover?

Biomatrix Healthcare Private Limited exports across 6 therapeutic categories. The largest are Antibiotics (37.5%, 4 products), Antimalarial & Antiparasitic (26.5%, 2 products), Respiratory & OTC (16.6%, 3 products).

Get Full Biomatrix Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.